The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Published version of a preprint
Abstract
It is generally thought that the anticancer efficacy of antibody–drug conjugates (ADC) relies on their internalization by cancer cells. However, recent work on an ADC that targets fibronectin in the tumor microenvironment suggests this may not be necessary. The alternatively spliced extra domains A and B (EDA and EDB) of fibronectin offer appealing targets for ADC development, because the antigen is strongly expressed in many solid human tumors and nearly undetectable in normal tissues except for the female reproductive system. In this study, we describe the properties of a set of ADCs based on an antibody targeting the alternatively spliced EDA of fibronectin coupled to one of a set of potent cytotoxic drugs (DM1 or one of two duocarmycin derivatives). The DM1 conjugate SIP(F8)-SS-DM1 mediated potent antitumor activity in mice bearing DM1-sensitive F9 tumors but not DM1-insensitive CT26 tumors. Quantitative biodistribution studies and microscopic analyses confirmed a preferential accumulation of SIP(F8)-SS-DM1 in the subendothelial extracellular matrix of tumors, similar to the pattern observed for unmodified antibody. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative and compatible with pharmaceutical development. Our findings offer a preclinical proof-of-concept for curative ADC targeting the tumor microenvironment that do not rely upon antigen internalization. Cancer Res; 74(9); 2569–78. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2007) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 819
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 767
Neri, D., & Bicknell, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1627 · Cited by 601
Self-citationJunttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 544
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L. R., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 423
Self-citationPotent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 403
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepúlveda, J., Burrone, Ó. R., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 354
Self-citation
Cited by
Sorted by citations
Items 101–130 of 130
Rodak, A., Stadlbauer, K., Bobbili, M. R., Smrzka, O. W., Rüker, F., & Wozniak‐Knopp, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914997 · Cited by 5
Cheung, C. H. P., Chong, T. H., Wei, T., Liu, H., & Li, X. (2023) · Angewandte Chemie · doi:10.1002/ange.202217150 · Cited by 4
Progress of nanoparticles research in cancer therapy and diagnosis
Neguț, I., Grumezescu, V., & Dorcioman, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46144-3.00006-4 · Cited by 4
Manabe, S. (2019) · Springer eBooks · doi:10.1007/978-4-431-56880-3_5 · Cited by 4
Kemmer, A., Bieber, K., Abadpour, A., Yu, X., Mitschker, N., Roth, S., Kauderer, C., Ludwig, R. J., Seeger, K., Köhl, J., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12804 · Cited by 3
Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)
Widdison, W. C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00100 · Cited by 3
Latest Tools in Fight Against Cancer: Nanomedicines
Trivedi, M., Johri, P. K., Singh, A., Singh, R., & Tiwari, R. (2020) · Springer eBooks · doi:10.1007/978-981-32-9898-9_6 · Cited by 3
Protein C-Terminal Tyrosine Conjugation via Recyclable Immobilized BmTYR
Ji, X., Zhu, N.-L., Ma, Y., Liu, J., & Hu, Y. (2022) · ACS Omega · doi:10.1021/acsomega.2c05794 · Cited by 3
Tumor Effect‐Site Pharmacokinetics: Mechanisms and Impact on Efficacy
Thurber, G. M. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse551 · Cited by 3
Collyer, S. E., Stack, G. D., & Walsh, J. J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220401105929 · Cited by 2
The promising expedition of the delivery systems for monoclonal antibodies
Megahed, M. A., El‐Sawy, H. S., & El‐Say, K. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819666-3.00003-1 · Cited by 2
Next‐Generation Antibody–Drug Conjugate Technologies
Han, A. Q., & Olson, W. C. (2016) · doi:10.1002/9781119060727.ch18 · Cited by 2
Yang, Y., Patel, J. M., Yang, R., Ma, F., Niu, X., Zhang, Y., Niedringhaus, T. P., Al-Sayah, M., & Yang, X. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05707-w · Cited by 1
Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance
Ye, L., Xiang, S., Xue, R., Zhang, Y., Wang, Y., Xiong, X., Qin, C., & Duan, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03981-3 · Cited by 1
Zhang, J., Zhu, L.-W., Ji, J., Tang, T.-M., Zhu, M.-J., & Yao, H. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.010 · Cited by 2
Payan, S., Montana, M., Curti, C., Greillier, L., & Vanelle, P. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00740-y · Cited by 1
Summary and Future Directions of ADCs
Zaro, J. L., Wang, J., & Shen, W. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-13081-1_14 · Cited by 1
Linker Design and Impact on ADC Properties
Frigerio, M., & Camper, N. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165153-00071 · Cited by 1
Antibody−drug conjugates: a new generation of cancer vaccines
Babar, Q. A., Maryam, Tahir, M. F., Khalid, A., & Ali, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00015-7 · Cited by 1
Quantitative analysis of cellular processing of Antibody-Drug Conjugates
Maass, K. F. (2016) · DSpace@MIT (Massachusetts Institute of Technology)
Nanoparticle theranostics targeting CLEC14A on tumour vasculature
Pearce, J. (2020) · University of Birmingham Institutional Research Archive (University of Birmingham)
Nanomedicines: Recent Progress, Impact and Challenges in Applications
Singh, A. (2021) · Asian Journal of Chemistry · doi:10.14233/ajchem.2021.23350
The Internalization and Therapeutic Activity of Antibody Drug Conjugates
Fan, J., & Chen, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-5638-6_3
Zhang, D., Guo, Y., Zhao, Y., Yu, L., Chang, Z., Pei, H., Huang, J., Chen, C., Xue, H., Xu, X., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14196634
De l’ifosfamide au géranyloxy-ifosfamide : pharmacomodulation pour cibler et moduler l’immunité
Delahousse, J. (2019) · theses.fr (ABES) · doi:10.70675/516a5d4ez81ccz485azbe9cze077be422c4a
Kizlik‐Masson, C. (2018) · theses.fr (ABES) · doi:10.70675/25332178z3663z43b5zb134z384f5624cda7
Nanomedicine targeting ECM stiffness: restoring mechanical homeostasis for cancer immunotherapy
Yang, M., Jia, H., Zhang, Y., Shen, X., Zhang, Y., Liu, Y., Jia, X., Yu, C., & Liu, Z. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103390
Metadata
- Authors
- Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D.
- Affiliations
- University of Lisbon (PT)
- Venue
- Cancer Research
- Published
- 2014-04-30
- Volume
- 74
- Issue
- 9
- Pages
- 2569-2578
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2073629335
- Cited by
- 130
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 16 · 2018: 17 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 6
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Cambridge University Engineering Department Publications Database (submittedVersion)
- Funders
- Novartis Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Kommission für Technologie und Innovation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, maytansinoids, DM1, fibronectin, tumor microenvironment, curative treatment, antigen uptake, extracellular matrix, tumor targeting, CT26 tumor, tissue distribution
- MeSH terms
- Animals, Antibodies, Antineoplastic Agents, Cricetulus, Female, Cricetinae, Humans, Maytansine, Mice, Inbred BALB C, Mice, Nude, Tissue Distribution, CHO Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Embryonal Carcinoma Stem Cells, Mice, 129 Strain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
